StreetInsider.com News Articles

William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage

Wed, 21 Oct 2026 12:30:00 -0400

CHICAGO--(BUSINESS WIRE)-- William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering.

Young joined William Blair in May 2026 as part of a broader investment in the firm’s equities platform. With 25 years of experience across biotechnology and healthcare, she brings a perspective shaped by roles on both Wall Street and within the industry, most recently as chief financial officer of Bicycle Therapeutics.

Young’s initial coverage spans 13 biotechnology companies: Ascentage Pharma Group (AAPG), Cytokinetics (CYTK), Edgewise Therapeutics (EWTX), Faeth Therapeutics (FTH),

William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage

Wed, 21 Oct 2026 12:30:00 -0400

Young’s initial coverage spans 13 biotechnology companies: Ascentage Pharma Group (AAPG), Cytokinetics (CYTK), Edgewise Therapeutics (EWTX), Faeth Therapeutics (FTH),

Prostate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase

Sat, 17 Oct 2026 08:30:00 -0400

– PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types –

– New members Orano Med, Telix and Siemens Healthineers join PCF and industry leaders at kickoff meeting at 2026 EANM Annual Congress to address key challenges impacting radiopharmaceutical development and patient access –

LOS ANGELES--(BUSINESS WIRE)-- The Prostate Cancer Foundation (PCF) today announced the expansion of its Radiopharmaceutical Think Tank, adding new members and establishing its 2026-2027 agenda, which is focused on accelerating development and patient access of novel radiopharmaceutical drugs for cancer treatment.

Prostate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase

Sat, 17 Oct 2026 08:30:00 -0400

– PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types –

Form 4/A BICYCLE THERAPEUTICS For: Oct 02 Filed by: Perry Jennifer Scott

Wed, 07 Oct 2026 18:25:00 -0400

si-local-file:///var/storage/secattach/20261007/27162178.html

Form 4 BICYCLE THERAPEUTICS For: Oct 02 Filed by: Lee Kevin

Tue, 06 Oct 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20261006/27156097.html

Form 4 BICYCLE THERAPEUTICS For: Oct 02 Filed by: Perry Jennifer Scott

Tue, 06 Oct 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20261006/27156098.html

Form 4 BICYCLE THERAPEUTICS For: Oct 02 Filed by: Hannay Michael Charles Ferguson

Tue, 06 Oct 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20261006/27156100.html

Form 4 BICYCLE THERAPEUTICS For: Oct 02 Filed by: Skynner Michael

Tue, 06 Oct 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20261006/27156101.html

Form 4 BICYCLE THERAPEUTICS For: Oct 02 Filed by: Swanton Robert Charles

Tue, 06 Oct 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20261006/27156103.html

Form 4 BICYCLE THERAPEUTICS For: Oct 02 Filed by: Thompson Travis Alvin

Tue, 06 Oct 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20261006/27155999.html

Form 3/A BICYCLE THERAPEUTICS For: Jun 22 Filed by: Thompson Travis Alvin

Tue, 06 Oct 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20261006/27155977.html

Form 144 BICYCLE THERAPEUTICS Filed by: Lee Kevin

Fri, 02 Oct 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20261002/27142210.html

Bicycle Therapeutics (BCYC) PT Lowered to $11 at Oppenheimer

Fri, 31 Jul 2026 08:11:51 -0400

Oppenheimer analyst Jay Olson lowered the price target on Bicycle Therapeutics (NASDAQ: BCYC) to $11.00 (from $36.00) while maintaining a Outperform rating.

Bicycle Therapeutics plc (BCYC) Misses Q2 EPS by 15c

Thu, 30 Jul 2026 07:52:00 -0400

Bicycle Therapeutics plc (NASDAQ: BCYC) reported Q2 EPS of ($0.72), $0.15 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $630 thousand versus the consensus estimate of $4.35 million.

For earnings history and earnings-related data on Bicycle Therapeutics plc (BCYC) click here.

Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

Thu, 30 Jul 2026 07:00:00 -0400

Data presented at AACR and ASCO provide further validation of the potential of Bicycle® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities